Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Molecular Docking and Simulation Analysis of Cyclopeptides as Anticancer Agents

Author(s): Abhishek Tiwari*, Varsha Tiwari, Suresh Kumar, Manish Kumar, Renu Saharan, Navneet Varma, Biswa Mohan Sahoo, Deepak Kaushik and Rajeev Kumar Sharma

Volume 18, Issue 3, 2023

Published on: 10 March, 2023

Page: [247 - 261] Pages: 15

DOI: 10.2174/1574885518666230222113033

Price: $65

conference banner
Abstract

Background: Cancer is a leading cause of death for people worldwide, in addition to the rise in mortality rates attributed to the Covid epidemic. This allows scientists to do additional research. Here, we have selected Integerrimide A, cordy heptapeptide, and Oligotetrapeptide as the three cyclic proteins that will be further studied and investigated in this context.

Methods: Docking research was carried out using the protein complexes 1FKB and 1YET, downloaded from the PDB database and used in the docking investigations. Cyclopeptides have been reported to bind molecularly to human HSP90 (Heat shock protein) and FK506. It was possible to locate HSP90 in Protein Data Banks 1YET and 1FKB. HSP90 was retrieved from Protein Data Bank 1YET and 1FKB. Based on these findings, it is possible that the anticancer effects of Int A, Cordy, and Oligo substances could be due to their ability to inhibit the mTOR rapamycin binding domain and the HSP90 Geldanamycin binding domain via the mTOR and mTOR chaperone pathways. During the calculation, there were three stages: system development, energy reduction, and molecular dynamics (also known as molecular dynamics). Each of the three compounds demonstrated a binding affinity for mTOR's Rapamycin binding site that ranged from -6.80 to -9.20 Kcal/mol (FKB12).

Results: An inhibition constant Ki of 181.05 nM characterized Cordy A with the highest binding affinity (-9.20 Kcal/mol). Among the three tested compounds, Cordy A was selected for MD simulation. HCT116 and B16F10 cell lines were used to test each compound's anticancer efficacy. Doxorubicin was used as a standard drug. The cytotoxic activity of substances Int A, Cordy A, and Oligo on HCT116 cell lines was found to be 77.65 μM, 145.36 μM, and 175.54 μM when compared to Doxorubicin 48.63 μM, similarly utilizing B16F10 cell lines was found to be 68.63 μM, 127.63 μM, and 139.11 μM to Doxorubicin 45.25 μM.

Conclusion: Compound Cordy A was more effective than any other cyclic peptides tested in this investigation.

« Previous Next »
Graphical Abstract

[1]
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11): e442.
[http://dx.doi.org/10.1371/journal.pmed.0030442] [PMID: 17132052]
[2]
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006; 367(9524): 1747-57.
[http://dx.doi.org/10.1016/S0140-6736(06)68770-9] [PMID: 16731270]
[3]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[4]
Karpuz M, Silindir-Gunay M, Ozer AY. Current and future approaches for effective cancer imaging and treatment. Cancer Biother Radiopharm 2018; 33(2): 39-51.
[http://dx.doi.org/10.1089/cbr.2017.2378] [PMID: 29634415]
[5]
Nobili S, Lippi D, Witort E, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res 2009; 59(6): 365-78.
[http://dx.doi.org/10.1016/j.phrs.2009.01.017] [PMID: 19429468]
[6]
Fridlender M, Kapulnik Y, Koltai H. Plant derived substances with anti-cancer activity: From folklore to practice. Front Plant Sci 2015; 6: 799.
[http://dx.doi.org/10.3389/fpls.2015.00799] [PMID: 26483815]
[7]
Chin YW, Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. AAPS J 2006; 8(2): E239-53.
[http://dx.doi.org/10.1007/BF02854894] [PMID: 16796374]
[8]
Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007; 9(12): 767-76.
[http://dx.doi.org/10.1007/s12094-007-0138-9] [PMID: 18158980]
[9]
Loffet A. Peptides as drugs: Is there a market? J Pept Sci 2002; 8(1): 1-7.
[http://dx.doi.org/10.1002/psc.366] [PMID: 11831558]
[10]
Hummel G, Reineke U, Reimer U. Translating peptides into small molecules. Mol Biosyst 2006; 2(10): 499-508.
[http://dx.doi.org/10.1039/b611791k] [PMID: 17216031]
[11]
Kwon YU, Kodadek T. Quantitative comparison of the relative cell permeability of cyclic and linear peptides. Chem Biol 2007; 14(6): 671-7.
[http://dx.doi.org/10.1016/j.chembiol.2007.05.006] [PMID: 17584614]
[12]
Chatterjee S, Bhattacharya S, Socinski MA, Burns TF. HSP90 inhibitors in lung cancer: Promise still unfulfilled. Clin Adv Hematol Oncol 2016; 14(5): 346-56.
[PMID: 27379696]
[13]
a) Ghaemmaghami S, Huh WK, Bower K, Howson RW. Global analysis of protein expression in yeast. Nature 2003; 425: 737-41.
[http://dx.doi.org/10.1038/nature02046];
b) Whitesell L, Lindquist SL. HSP90 and the chaperoning. Nature 2005; 5: 761-72.
[http://dx.doi.org/10.1038/nrc1716]
[14]
Abbasi M, Sadeghi-Aliabadi H, Amanlou M. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation. Daru 2017; 25(1): 17.
[http://dx.doi.org/10.1186/s40199-017-0182-0] [PMID: 28666484]
[15]
Sawai A, Chandarlapaty S, Greulich H, et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008; 68(2): 589-96.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-1570] [PMID: 18199556]
[16]
Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003; 14(8): 1169-76.
[http://dx.doi.org/10.1093/annonc/mdg316] [PMID: 12881371]
[17]
Jayaraman T, Brillantes AM, Timerman AP, et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 1992; 267(14): 9474-7.
[http://dx.doi.org/10.1016/S0021-9258(19)50114-4] [PMID: 1374404]
[18]
Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009; 30(16): 2785-91.
[http://dx.doi.org/10.1002/jcc.21256] [PMID: 19399780]
[19]
He K, Zheng X, Li M, Zhang L, Yu J. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation. Oncogene 2016; 35(2): 148-57.
[http://dx.doi.org/10.1038/onc.2015.79] [PMID: 25867072]
[20]
Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008; 128(4): 980-7.
[http://dx.doi.org/10.1038/sj.jid.5701074] [PMID: 17914450]
[21]
Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anti-cancer activities. Cancer Lett 2010; 290(1): 24-35.
[http://dx.doi.org/10.1016/j.canlet.2009.07.010] [PMID: 19850405]
[22]
Van Duyne GD, Standaert RF, Schreiber SL, Clardy J. Atomic structure of the rapamycin human immunophilin FKBP-12 complex. J Am Chem Soc 1991; 113(19): 7433-4.
[http://dx.doi.org/10.1021/ja00019a057]
[23]
Ivanova L, Tammiku-Taul J, García-Sosa AT, Sidorova Y, Saarma M, Karelson M. Molecular Dynamics Simulations of the Interactions between glial cell line-derived neurotrophic factor family receptor gfrα1 and small-molecule ligands. ACS Omega 2018; 3(9): 11407-14.
[http://dx.doi.org/10.1021/acsomega.8b01524] [PMID: 30320260]
[24]
Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W. Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the opls force field. J Chem Theory Comput 2010; 6(5): 1509-19.
[http://dx.doi.org/10.1021/ct900587b] [PMID: 26615687]
[25]
Kuttan R, Bhanumathy P, Nirmala K, George MC. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 1985; 29(2): 197-202.
[http://dx.doi.org/10.1016/0304-3835(85)90159-4] [PMID: 4075289]
[26]
Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell Biosci 2020; 10(1): 31.
[http://dx.doi.org/10.1186/s13578-020-00396-1] [PMID: 32175074]
[27]
Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin Cancer Res 2012; 18(1): 64-76.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-1000] [PMID: 22215907]
[28]
Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 1997; 89(2): 239-50.
[http://dx.doi.org/10.1016/S0092-8674(00)80203-2] [PMID: 9108479]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy